The global COPD and asthma devices market is expected to reach $51,628.58 million by 2027, registering a CAGR of 4.30% during 2020-2027.
Chronic obstructive pulmonary disease (COPD) and asthma devices are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. Moreover, COPD and asthma are the respiratory diseases that cause difficulty in breathing and a blockage in the airways of lungs. Furthermore, according to the Global Health Organization (WHO), in 2016, around 251 million cases of COPD were estimated globally. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.
Chronic obstructive pulmonary disease (COPD) and asthma are a chronic inflammatory lung disorder. The COPD and Asthma symptoms & causes are equivalent to the symptoms of the pandemic coronavirus disease 2019. In addition, asthmatic patients are more prone to the Covid-19 symptoms. According to the paper published by the Journal of Allergy and Clinical Immunology, in 2020, the patients with the asthma and COPD appear to have increased their adherence to inhalers medications during the Covid-19. Moreover, according to the National Health Service (NHS) in 2020, the number of inhalers prescribed by general practitioners in England increased by 63% between February 2020 and March 2020. Further, in some parts of the country such as U.K and U.S. are experiencing shortages of albuterol inhalers, because hospitals are using them more for COVID-19 patients. Thus, Covid-19 has uplifted the growth and opportunities for the manufacturers of COPD and Asthma devices during the forecast period.
The major factors that contribute toward the growth of the COPD and asthma devices market include rise in prevalence of respiratory diseases such as COPD, asthma, and emphysema; growing need for rescue medication during sudden asthmatic attack; and burgeoning demand for short-term, effective medication. Moreover, increase in focus of manufacturers toward the development of advanced, portable inhalation devices, and government initiatives toward the spread of awareness for COPD and asthma symptoms are expected to boost the market growth. However, the factors such as environmental concerns associated with metered dose inhalers (MDI), high cost of some inhalation devices and treatment, rise in price competition, and deterioration of material quality are expected to restrain the market growth. In addition, incompetent reimbursement support and patent expiration for blockbuster drugs hamper the market growth. On the contrary, rise in use of the smart inhaler devices that are more intuitive and drive the patient engagement and adherence while increasing treatment effectiveness is anticipated to provide lucrative growth opportunity for the market growth in the near future.
Global Copd And Asthma Devices Market Segmentation
The global COPD and asthma devices market is segmented on the basis of product type, indication, distributional channel, and region. Based on the device type, the market is segmented into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on indication, the market is divided into asthma and COPD. Based on distribution channel, it is segregated into retail pharmacies, online pharmacies, and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of respective countries.
Segment Review
On the basis of product type, the market is divided into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. In addition, the inhalers segment held the major COPD and asthma devices market share in 2019, owing to the factors such as inhalation route is the fastest and most effective method of delivering medications to the respiratory system during treatment of COPD and asthma.
By Product Type
Inhalers segment holds a dominant position in 2019
By distribution channel, the retail pharmacies segment occupied the largest COPD and asthma devices market share in 2019 and is also expected to exhibit fastest growth rate during the forecast period. The growth of the segment is due to factors such as it is the oldest and most conventional medium distributing the respiratory devices to the consumers, owing to its large chain of distribution network of pharmacies store.
By Distribution Channel
Online Pharmacies segment is projected as one of the most lucrative segment.
In 2019, North America accounted for the major share in 2019 for COPD and asthma devices market size and is expected to continue this trend, owing to the widespread and early adoption of inhalers & nebulizers and large pool of patients suffering from respiratory diseases. Moreover, the Asia-Pacific region is expected to grow rapidly due to rise in healthcare expenditure, growth in awareness of advanced portable COPD & asthma devices, and increase in disposable income.
By Region
Asia-Pacific region would exhibit the highest CAGR of 5.0% during 2019-2027.
Key Benefits For Stakeholders
- This report entails a detailed quantitative analysis along with the current global COPD and asthma devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
- The COPD and asthma devices market forecast is studied from 2020 to 2027.
- The COPD and asthma devices market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
COPD and Asthma Devices Market Report Highlights
| Aspects | Details |
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 By PRODUCT |
|
 By INDICATION |
|
 Key Market Players | Koninklijke Philips N.V. (Philips), GlaxoSmithKline Plc, .GF Health Products, Inc., PARI medical Holding GMBH, Smith’s Group Plc, 3M COMPANY, Novartis AG, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Aerogen, Inc., Baxter International Inc. |
Analyst Review
The use of inhalers and nebulizers has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of this market. Inhalers are used as handheld devices, whereas nebulizers have wide acceptance in home care treatments for COPD and asthma. The market is driven by the growing patient COPD and asthmatic population, as well as FDA approvals for the novel products and its wide acceptance among the patient population. Increase in government initiatives to control COPD and asthma further fuels the growth for this market.
The inhalers market consists of three types of inhalers, namely, drug powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). The use of MDIs releases environmentally hazardous gases, namely CFC and HFA, which has led the healthcare regulatory authorities to ban the production and usage of MDIs. This is likely to adversely affect the growth of MDIs market during the analysis period.
Whereas, The SMIs segment is estimated to register a higher CAGR as compared to its peers as SMI is three times more effective than DPIs and MDIs.
The total market value of COPD and Asthma Devices market is $36,457.43 million in 2019.
The forcast period for COPD and Asthma Devices market is 2020 to 2027
The market value of COPD and Asthma Devices market in 2019 is $51,628.58 million.
The base year is 2019 in COPD and Asthma Devices market
Top companies such as, AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, 3M COMPANY, GF Health Products, GlaxoSmithKline Plc, Koninklijke Philips N.V.held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
Inhaler segment is the most influencing segment owing to owing to the factors such as inhalation route is the fastest and most effective method of delivering medications to the respiratory system during treatment of COPD and asthma.
The major factor that fuels the growth of the global COPD and Asthma Devices market includes The demand for COPD and asthma devices is on a rise, owing to surge in incidence of chronic diseases such as respiratory disorders & COPD and increasing population of smokers. Furthermore, rise in portable aerosol inhalers devices across the globe which contribute to the growth of the market.
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 5.0%. This is due to rising healthcare expenditure, growing awareness of advanced portable COPD & asthma devices, and increasing disposable income.
Chronic obstructive pulmonary disease (COPD) and asthma devices, also known as pulmonary drug delivery devices.
The COPD and Asthma Devices are used as a permanent treatment or rescue therapy for respiratory diseases, Further It is the most advanced mode of drug administration in which the drug is directly delivered to the lungs to provide a systemic effect. These two devices are frequently used in the treatment of COPD and asthma which includes inhalers and nebulizers.
Loading Table Of Content...
